|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||80.30 - 81.10|
|52-week range||80.30 - 81.10|
|Beta (5Y monthly)||0.79|
|PE ratio (TTM)||23.76|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
LURE, France, March 06, 2023--Regulatory News: Vetoquinol (Paris:VETO), the trusted partnerFor over 90 years, the company has been a key player in animal health. Today, it is one of the world's top 10 veterinary pharmaceutical companies. Since its creation in 1933, Vetoquinol has worked alongside veterinarians, breeders, pet owners and experts, devoting its efforts to the well-being and improvement of animal health.Today, the company offers a wide range of solutions for pets and livestock and fo
LURE, France, January 18, 2023--Regulatory News: Matthieu Frechin, CEO of Vetoquinol (Paris:VETO), said: "The Covid-19 effect has led to exceptional growth in animal health markets in 2020 and 2021. This long-term trend remains, despite a weaker market in 2022. Our strategy of focusing on targeted market segments will enable us to continue to deliver profitable growth driven by our Essentials products."
LURE, France, January 10, 2023--Regulatory News: Vetoquinol (Paris:VETO) published its calendar of financial communication for 2023.